The long-term evolution of botulinum toxin dosage in the treatment of hemifacial spasms;Evolución a largo plazo de la dosis de toxina botulínica en el tratamiento del espasmo hemifacial

Revista de Neurologia

Volumn 39, Issue 6, 2004, Pages 599-

  Garcia Torres M A ^a,b   Garcia Ruiz Espiga P J ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b Clínica Nuestra Señora de la Concepción   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BOTULINUM TOXIN A; CLONAZEPAM;

ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; DOSE CALCULATION; DOSE RESPONSE; HEMIFACIAL SPASM; HUMAN; INFANT; LONG TERM CARE; PATIENT SATISFACTION; TREATMENT OUTCOME;

EID: 8144221031     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3906.2004134     Document Type: Article

References (4)

1. Wang A, Jankovic J. Hemifacial spasm: clinical findings and treatment. Muscle Nerve 1998; 21: 1740-7.
2. Jitpimolmard S, Tiamkao S, Laopaiboon M. Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases. J Neurol Neurosurg Psychiatry 1998; 64: 751-7.
3. Van den Bergh P, Francart J, Mourin S, Kollmann P, Laterre E. Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve 1995; 18: 720-9.
4. Defazio G, Abbruzzese G, Girlanda P, Vacca L, Currà A, De Salvia R, et al. Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol 2002; 59: 418-20.